Forecast Ledgerinterventional psychiatry and psychedelic medicineQuoted, dated predictions scored against public outcomes under one written method. Every score links to the words, the rule and the evidence.

Not admitted · Third-party claim

Rules 1.1.0 · as of 14 Sep 2026

Quote

Third-party claim

“Respondents are most likely to offer psilocybin to patients if it is FDA approved (60 percent), followed by ketamine (50 percent) and MDMA (40 percent).”
· A New White Paper about Psychedelic Medicine and it's Economics · substack post

Additional finding in the press release: which psychedelic therapies providers would offer if FDA approved; the release notes only ketamine is currently FDA approved.

A quoted or paraphrased claim by someone else that the author does not adopt as their own.